Ipratropium bromide and Aggrastat drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ipratropium bromide and Aggrastat. Common interactions include haematoma among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people who take Ipratropium bromide and Aggrastat have. It is created by eHealthMe based on reports of 9 people who take Ipratropium bromide and Aggrastat from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 30, 2022

9 people who take Ipratropium bromide and Aggrastat together, and have interactions are studied.


What is Ipratropium bromide?

Ipratropium bromide has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 15,250 Ipratropium bromide users for its effectiveness, alternative drugs and more.

What is Aggrastat?

Aggrastat has active ingredients of tirofiban hydrochloride. eHealthMe is studying from 3,469 Aggrastat users for its effectiveness, alternative drugs and more.

Number of Ipratropium bromide and Aggrastat reports submitted per year:

Ipratropium bromide and Aggrastat drug interactions.

Common Ipratropium Bromide and Aggrastat drug interactions by gender *:

female:

  1. Haematoma
  2. Arteriovenous fistula
  3. Groin pain
  4. Cardiogenic shock
  5. Ecchymosis
  6. Haemoptysis
  7. Haemorrhage
  8. Injection site haemorrhage
  9. Renal failure acute

male:

  1. Dyspnoea
  2. Haematoma
  3. Rigors
  4. Vasodilatation
  5. Vein disorder
  6. Vein distended
  7. Venous pressure jugular increased
  8. Haemorrhage
  9. Haematocrit decreased
  10. Pulmonary embolism

Common Ipratropium Bromide and Aggrastat drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Arteriovenous fistula
  2. Groin pain
  3. Haematoma
  4. Injection site haemorrhage

60+:

  1. Haematoma
  2. Haemorrhage
  3. Haemoptysis
  4. Hypersensitivity
  5. Pulmonary haemorrhage
  6. Renal failure acute
  7. Rigors
  8. Vasodilatation
  9. Vein disorder
  10. Vein distended

* Approximation only. Some reports may have incomplete information.

Do you take Ipratropium bromide and Aggrastat?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Ipratropium bromide and Aggrastat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ipratropium bromide side effects:

Browse all side effects of Ipratropium bromide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Aggrastat side effects:

Browse all side effects of Aggrastat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ipratropium bromide interactions:

Browse all interactions between Ipratropium bromide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Aggrastat interactions:

Browse all interactions between Aggrastat and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ipratropium bromide and tirofiban hydrochloride (the active ingredients of Ipratropium bromide and Aggrastat, respectively), and Ipratropium bromide and Aggrastat (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Ipratropium bromide and Aggrastat.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: